Ophthalmology · Boston, MA
NPI
1952382780
Since 2005
Specialty
Ophthalmology
Code 207W00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
50 Staniford St, Suite 600
Boston, MA, 02114
Phone (617) 367-4800
Groups this clinician bills Medicare through
Medicare paid, 2024
$564K
7,005 services
Medicare patients, 2024
1,774
Average age 79
Drug cost, 2024
$1.3M
7,869 prescriptions
Company payments, 2025
$378
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Laura C Fine was code 92014 (ophthalmological e&m), 1,350 times for 1,300 patients. In total Laura C Fine billed 7,005 services in 39 codes, and Medicare paid $564K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-12-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 92014 Ophthalmological E&M | Office | 1,350 | 1,300 | $93.54 | $126K |
| 92083 Vision, Hearing, and Speech Services | Office | 903 | 856 | $50.31 | $45K |
| 66984 Cataract Surgery | Office | 895 | 22 | $1.04 | $930 |
| 92133 Computerized Ophthalmic Imaging | Office | 885 | 877 | $27.59 | $24K |
| 92012 Ophthalmological E&M | Office | 740 | 518 | $71.01 | $53K |
| 99213 Office E&M - Established | Office | 488 | 351 | $66.36 | $32K |
| 92136 Ultrasound - Nonspecific | Office | 427 | 325 | $32.45 | $14K |
| 66984 Cataract Surgery | Facility | 404 | 243 | $442.39 | $179K |
| 92134 Computerized Ophthalmic Imaging | Office | 255 | 229 | $31.79 | $8,108 |
| 66821 Cataract Surgery | Facility | 135 | 130 | $280.91 | $38K |
| 92020 Ophthalmological E&M | Office | 130 | 119 | $21.61 | $2,809 |
| 92004 Ophthalmological E&M | Office | 94 | 94 | $100.94 | $9,489 |
| 92132 Computerized Ophthalmic Imaging | Office | 60 | 60 | $23.30 | $1,398 |
| 99204 Office E&M - New | Office | 58 | 58 | $135.41 | $7,854 |
| 76514 Ultrasound - Nonspecific | Office | 34 | 34 | $8.99 | $306 |
By year: 2022 $550K for 6,473 services; 2023 $569K for 6,433 services; 2024 $564K for 7,005 services.
Medicare prescription drug claims, 2024
In 2024, the drug Laura C Fine prescribed most often to Medicare patients was Latanoprost, with 1,906 prescriptions and refills. In total Laura C Fine wrote 7,869 Medicare prescriptions that cost $1.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Latanoprost Generic | 1,906 | 4,950 | 605 | $30K |
| Timolol Maleate Generic | 1,018 | 2,560 | 338 | $22K |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 584 | 1,511 | 208 | $14K |
| Brimonidine Tartrate Generic | 569 | 1,403 | 194 | $18K |
| Prednisolone Acetate Generic | 407 | 575 | 277 | $18K |
| Lumigan Bimatoprost | 397 | 870 | 111 | $252K |
| Dorzolamide Hcl Generic | 293 | 701 | 110 | $7,182 |
| Rhopressa Netarsudil Mesylate | 255 | 483 | 66 | $181K |
| Ofloxacin Generic | 188 | 222 | 129 | $2,585 |
| Erythromycin Erythromycin Base | 149 | 159 | 100 | $1,883 |
| Brinzolamide Generic | 147 | 303 | 42 | $35K |
| Alphagan P Brimonidine Tartrate | 146 | 292 | 41 | $85K |
| Pilocarpine Hcl Generic | 139 | 332 | 39 | $9,070 |
| Rocklatan Netarsudil Mesylat/Latanoprost | 130 | 267 | 40 | $105K |
| Tafluprost Tafluprost/Pf | 120 | 268 | 40 | $25K |
Brand drugs: 2,640 claims; generic drugs: 5,229 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Laura C Fine $378 ($378 in general payments such as food, travel and fees) from 3 companies. The largest payer was Harrow Eye, LLC with $154.
| Company | Payments | Amount |
|---|---|---|
| Harrow Eye, LLC | 1 | $154 |
| Dompe US, Inc. | 1 | $120 |
| Alcon Vision LLC ALC | 3 | $104 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.